Clinical trials
Active, not recruiting Phase 2 Leukemia, Lymphocytic, Chronic, B-Cell trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
49 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 8 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 49 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 9 |
| City of Hope Medical Center | 6 |
| Memorial Sloan Kettering Cancer Center | 4 |
| Center for International Blood and Marrow Transplant Research | 2 |
| Dana-Farber Cancer Institute | 2 |
| Mayo Clinic | 2 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
| Weill Medical College of Cornell University | 2 |
| AbbVie | 1 |
| Acerta Pharma BV | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 49 |
| Leukemia | 9 |
| Lymphoma | 6 |
| Lymphoma, Non-Hodgkin | 5 |
| Lymphoproliferative Disorders | 5 |
| Myelodysplastic Syndromes | 5 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 |
| Leukemia, Myeloid, Acute | 4 |
| Lymphoma, Mantle-Cell | 4 |
| Myeloproliferative Disorders | 4 |
Trials
Showing 1 to 25 of 49. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.